Idarucizumab: First Global Approval

Drugs

Volumn 75, Issue 18, 2015, Pages 2155-2161

  Burness, Celeste B ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; IDARUCIZUMAB; PLACEBO; ANTIDOTE; ANTITHROMBIN; DABIGATRAN; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; BACKACHE; BLEEDING; CANADA; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; EMERGENCY SURGERY; EUROPEAN MEDICINES AGENCY; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERVENTILATION; IMMUNOGENICITY; INFUSION RELATED REACTION; INJURY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; SKIN IRRITATION; ADULT; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; HEMORRHAGE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIDOTES; ANTITHROMBINS; BLOOD COAGULATION; DABIGATRAN; DRUG APPROVAL; HEMORRHAGE; HUMANS;

EID: 84949191790     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0508-5     Document Type: Article

References (28)

1. ® (dabigatran etexilate mesylate) capsules for oral use: US prescribing infomation. 2015. http://www.boehringer-ingelheim.com/. Accessed 19 Oct 2015.
2. European Medicines Agency. Pradaxa 110 mg hard capsules: summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 19 Oct 2015.
3. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombol. 2015;39(3):395-402.
4. Costin J, Ansell J, Laulicht B, et al. Reversal agents in development for the new oral anticoagulants. Postgrad Med. 2014;126(7):19-24.
5. ® (idarucizumab) injection, for intravenous use: US prescribing information. 2015. http://us.boehringer-ingelheim.com. Accessed 2015.
6. ® (dabigatran etexilate mesylate) receives FDA breakthrough therapy designation [media release]. 26 Jun 2014.
7. Boehringer Ingelheim. FDA grants priority review to Boehringer Ingelheim's biologics license application for idarucizumab [media release]. 23 Apr 2015.
8. FDA. FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa [media release]. Accessed 16 Oct 2015. http://fda.gov.
9. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680-90.
10. EMA. EMA fast-tracks antidote to anticoagulant Pradaxa [media release]. http://www.ema.europa.eu/. Accessed 25 Sep 2015.
11. ® (dabigatran etexilate mesylate) [media release]. http://us.boehringer-ingelheim.com/news-events/press-releases/press-release-archive/2015/10-16-2015-fda-approves-praxbind-idarucizumab-specific-reversal-agent-pradaxa-dabigatran-etexilate-mesylate.html. Accessed 16 Oct 2015.
12. ®), to EMA, FDA and Health Canada [media release]. Accessed 3 Mar 2015.
13. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554-62.
14. Grottke O, Honickel M, van Ryn J, et al. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. 2015;66(13):1518-9.
15. Honickel M, Grottke O, Van Ryn J, et al. Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs [abstract no. P99]. Crit Care. 2014;18(Suppl 1):S34-5.
16. Honickel M, van Ryn J, Rossaint R, et al. Effects of idarucizumab, given as a split dose, in a blunt liver double trauma model in pigs receiving dabigatran [abstract no. OR067]. J Thromb Haemost. 2015;13(Suppl 2):119.
17. Grottke O, Honickel M, Van Ryn J, et al. Dabigatran-induced anticoagulant and bleeding effects can be reversed with both prothrombin complex concentrates and a specific antidote (idarucizumab) in a lethal porcine polytrauma model [abstract no. 4844]. Eur Heart J. 2014;35(Abstract Supplement):863.
18. Grottke O, Van Ryn J, Rossaint R. In a trauma experimental pig model prothrombin complex concentrates and a specific antidote (idarucizumab) are effective to reverse the anticoagulant effects of dabigatran [abstract no. P118]. Crit Care. 2014;18(Suppl 1):S41.
19. Honickel M, Braunschweig T, Ryn JV, et al. Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model [abstract no. P351]. Crit Care. 2015;19(Suppl 1):S123.
20. Honickel M, Braunschweig T, Rossaint R, et al. Prothrombin complex concentrate or idarucizumab in combination with fibrinogen plus tranexamic acid are equally effective in a dabigatran anticoagulation experimental polytrauma model [abstract no. 4978]. Eur Heart J. 2015;36(Abstract Supplement):861.
21. Honickel M, Treutler S, van Ryn J, et al. Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost. 2015;113(4):728-40.
22. Grottke O, van Ryn J, Zentai C. Resuscitation with different infusion solutions does not influence binding of dabigatran to its specific antidote in a pig model of hemorrhagic shock [abstract]. Circulation. 2013;128(Suppl):356.
23. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943-51.
24. Stangier J, Schmohl M, Glund S, et al. Idarucizumab does not have prothrombotic effects: assessment of coagulation markers in healthy volunteers [abstract no. OR320]. J Thromb Haemost. 2015;13(Suppl 2):217.
25. van Ryn J, Schmoll M, Pillu H, et al. Effect of dabigatran on the ability to generate fbrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy volunteers: an exploratory marker of blood loss [abstract no. 18403]. Circulation. 2014;130(Suppl 2).
26. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-20.
27. Levy JH, Verhamme P, Sellke FW, et al. Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study [abstract no. P5967]. Eur Heart J. 2015;36(Abstract Supplement):1043.
28. Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects [abstract no. 344]. 56th Annual Meeting and Exposition of the American Society of Hematology; 8 Dec 2014; San Francisco, CA.